Selected publications
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. 2018 Academic Article GET IT
- Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. Journal of Translational Medicine. 2017 Academic Article GET IT
- The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. Journal of Translational Medicine. 2017 Editorial Article GET IT
-
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.
European Journal of Cancer.
2017
Review
GET IT
Times cited: 24 -
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody.
Clinical Cancer Research.
2017
Academic Article
GET IT
Times cited: 22 -
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
The lancet oncology.
2017
Academic Article
GET IT
Times cited: 16 -
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.
European Journal of Cancer.
2017
Academic Article
GET IT
Times cited: 7 -
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab.
Clinical Cancer Research.
2016
Academic Article
GET IT
Times cited: 76 -
Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Journal of Translational Medicine.
2016
Article
GET IT
Times cited: 8 - Perspectives in immunotherapy: Meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015. Journal for ImmunoTherapy of Cancer. 2016 Academic Article GET IT
-
Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab.
Clinical Cancer Research.
2016
Academic Article
GET IT
Times cited: 31 -
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.
European Journal of Cancer.
2016
Academic Article
GET IT
Times cited: 13 -
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab.
Clinical Cancer Research.
2016
Academic Article
GET IT
Times cited: 97 -
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial.
The lancet oncology.
2015
Academic Article
GET IT
Times cited: 341 -
Expanded access programmes: Patient interests versus clinical trial integrity.
The lancet oncology.
2015
Comment
GET IT
Times cited: 3 -
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial.
The lancet oncology.
2015
Academic Article
GET IT
Times cited: 533 -
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study.
The lancet oncology.
2014
Academic Article
GET IT
Times cited: 449 -
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.
Journal of Pathology.
2014
Review
GET IT
Times cited: 372 -
Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases.
Expert Review of Dermatology.
2013
Report
GET IT
Times cited: 3 -
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial.
The lancet oncology.
2012
Academic Article
GET IT
Times cited: 486